The industry is engaging new operating models both in drug development and in discovery research and with the execution of clinical trials, shifting toward strategic partnerships between pharma and other organizations. The representation of this conference is evidence of that. As the research and development ecosystem expands, there is an increasing need for robust connectivity between organizations and an effective means to maintain control and ensure high quality data. This has challenged us, at Pfizer, to reassess how we can facilitate better communication and partnership and ease execution of clinical research and this address offers insights, particularly into how technology can enable the industry to progress in some of these new operating models.
展开▼
